Oral paclitaxel before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with triple-negative breast cancer that has not spread to other parts of the body.
- Your tumor is large enough or has spread to lymph nodes, but not too early stage.
- You have not had prior treatment for this breast cancer.
- You are generally healthy enough for chemo, with good heart, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.